Medicare Expands GLP-1 Coverage to 3.4 Million Seniors Under New CMS Rule

After years of exclusion, Medicare has opened the door for millions of seniors to access life-changing GLP-1 medications. On March 15, 2026, the Centers for Medicare and Medicaid Services published its final rule amending Part D coverage criteria for glucagon-like peptide-1 receptor agonists, with CMS projecting the rule will expand coverage eligibility to approximately 3.4 million Medicare beneficiaries who were previously excluded solely because their GLP-1 prescriptions were written for weight management rather than a named chronic disease.

The change represents a seismic shift for seniors like Maria Delgado, a 68-year-old retired teacher in Albuquerque who had been rationing her semaglutide doses to afford the nearly $1,000 monthly cost. After cutting doses to afford the $936 monthly cost her Medicare plan would not cover, in January 2026, her pharmacist called with news she had stopped expecting: her prescription was now covered. She paid $35 at the counter.

The Cardiovascular Coverage Pathway

The key to this expansion lies in how CMS now interprets GLP-1 prescriptions. CMS's legal position, outlined in a February 2026 guidance memo, holds that when a GLP-1 is prescribed to reduce cardiovascular risk in a patient with obesity — a use now supported by clinical trial data — the drug qualifies as a cardiovascular medication, not a weight-loss drug, for coverage purposes.

This reinterpretation is grounded in robust clinical evidence. The regulatory change is grounded substantially in the SELECT trial, a landmark cardiovascular outcomes study funded by Novo Nordisk and published in the New England Journal of Medicine in late 2023. The trial enrolled more than 17,600 adults with overweight or obesity and established cardiovascular disease but without diabetes. Participants receiving weekly semaglutide 2.4 mg injections experienced a 20 percent reduction in major adverse cardiovascular events compared to placebo over an average follow-up of 34 months.

The FDA's approval of semaglutide's cardiovascular indication in March 2024 provided the regulatory foundation CMS used to justify this coverage expansion.

Implementation Challenges and Real-World Solutions

While the rule change is official, implementation hasn't been seamless. Individual plan formularies may require updated prior authorization submissions, and not all pharmacies have received updated billing instructions as of April 2026.

For seniors navigating this new landscape, advocacy is crucial. Medicare beneficiaries who believe they qualify under the new rule should contact their Part D plan directly before assuming coverage has been automatically activated. CMS advises beneficiaries to call 1-800-MEDICARE with coverage disputes.

Patient advocates have long criticized what they saw as arbitrary barriers. The organization has for years tracked what it describes as systematic undertreatment of obesity in federal insurance programs, citing barriers that it argues have no equivalent for other chronic conditions like hypertension or hyperlipidemia.

The Financial and Political Reality

The coverage expansion comes with significant cost implications. The Congressional Budget Office, in a preliminary analysis released in January 2026, projected that extending GLP-1 coverage to Medicare's obesity-plus-cardiovascular population could increase federal spending by approximately $35 billion over a 10-year window — a figure that opponents in the House Budget Committee have used to argue against the rule.

However, proponents argue this represents long-term cost savings through prevented cardiovascular events and hospitalizations. A 2024 analysis published in Health Affairs estimated that universal GLP-1 access for eligible patients could prevent approximately 300,000 cardiovascular events over a decade.

Additional Medicare Programs on the Horizon

This rule change is the first of several expansions. Medicare is preparing additional GLP-1 access programs for 2026. Prior to the launch of the BALANCE model, CMS also plans to implement a new Medicare GLP-1 payment demonstration beginning in July 2026, which will serve as a short-term bridge to the model. Under the demonstration eligible Medicare beneficiaries will pay $50 for a month of GLP-1 medications.

The broader BALANCE model will launch in January 2027, potentially expanding access further while controlling costs for both patients and taxpayers.

What This Means for You

If you're on Medicare and have been denied GLP-1 coverage in the past, this rule change could transform your access to these medications. The key is understanding that coverage now depends on how your doctor codes the prescription, not what you're prescribed.

To qualify under the new pathway, you need documented cardiovascular disease (like previous heart attack, stroke, or coronary artery disease) plus a BMI of 27 or higher. Your physician will need to prescribe the medication specifically for cardiovascular risk reduction, not weight loss.

Don't assume coverage is automatic. Contact your Medicare Part D plan directly to understand their specific prior authorization requirements. If you're still facing barriers or need help navigating the coverage requirements, comparing telehealth providers that specialize in working with Medicare patients can help you understand the new coverage pathways and ensure your prescription is coded correctly.

For those still facing coverage gaps or looking to understand all your options, our comprehensive cost guide can help you explore alternative payment methods while working through the Medicare approval process.